TargetMol

2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxylic acid

Product Code:
 
TAR-T67877
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T67877-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67877-5mg5mg£431.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67877-10mg10mg£600.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67877-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67877-50mg50mg£1,187.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67877-100mg100mg£1,581.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67877-500mg500mg£3,107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxylic acid is commonly used to synthesize compounds with anticancer and antitumor properties.
CAS:
1502645-66-0
Molecular Weight:
248.21
Purity:
0.98
SMILES:
O=C(O)C1=NC(=NC=C1)C=2C(F)=CC=CC2OC

References

Vechorkin, et al. Preparation of N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for treating cancer. WO2019164846A1.